S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
DOW New Hghs Coming Sooner Than Later
Will Advanced Micro Devices Follow NVIDIA Higher? 
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
DOW New Hghs Coming Sooner Than Later
Will Advanced Micro Devices Follow NVIDIA Higher? 
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
DOW New Hghs Coming Sooner Than Later
Will Advanced Micro Devices Follow NVIDIA Higher? 
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
DOW New Hghs Coming Sooner Than Later
Will Advanced Micro Devices Follow NVIDIA Higher? 
NASDAQ:IDXX

IDEXX Laboratories - IDXX Price Target & Analyst Ratings

$495.40
+12.14 (+2.51%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$486.29
$496.69
50-Day Range
$454.86
$514.59
52-Week Range
$317.06
$560.92
Volume
381,308 shs
Average Volume
375,496 shs
Market Capitalization
$41.07 billion
P/E Ratio
61.69
Dividend Yield
N/A
Price Target
$514.75

IDEXX Laboratories Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 8 Analyst Ratings

Consensus Analyst Price Target

$514.75
3.91% Upside
High Prediction$600.00
Average Prediction$514.75
Low Prediction$415.00
TypeCurrent
3/22/22 to 3/22/23
1 Month Ago
2/20/22 to 2/20/23
3 Months Ago
12/22/21 to 12/22/22
1 Year Ago
3/22/21 to 3/22/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$514.75$514.75$473.13$702.40
Predicted Upside3.91% Upside13.87% Upside19.75% Upside10.18% Upside
Get IDEXX Laboratories Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

IDXX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IDXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IDEXX Laboratories Stock vs. The Competition

TypeIDEXX LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.64
2.47
Consensus RatingModerate BuyBuyHold
Predicted Upside3.91% Upside1,901.95% Upside20.88% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/8/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$582.00 ➝ $590.00+16.21%
2/7/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$525.00 ➝ $550.00+13.28%
2/7/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$470.00 ➝ $600.00+23.58%
1/25/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$465.00 ➝ $530.00+9.24%
11/15/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$573.00 ➝ $543.00+23.80%
8/8/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$500.00 ➝ $420.00+2.40%
8/3/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$415.00+1.30%
5/5/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$550.00 ➝ $470.00+14.27%
2/2/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Daniels
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/13/2021Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$735.00 ➝ $770.00+13.96%
7/12/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
(Data available from 3/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












IDXX Price Target - Frequently Asked Questions

What is IDEXX Laboratories's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for IDEXX Laboratories stock is Moderate Buy based on the current 2 hold ratings and 6 buy ratings for IDXX. The average twelve-month price prediction for IDEXX Laboratories is $514.75 with a high price target of $600.00 and a low price target of $415.00. Learn more on IDXX's analyst rating history.

Do Wall Street analysts like IDEXX Laboratories more than its competitors?

Analysts like IDEXX Laboratories more than other Medical companies. The consensus rating for IDEXX Laboratories is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how IDXX compares to other companies.

Does IDEXX Laboratories's stock price have much upside?

According to analysts, IDEXX Laboratories's stock has a predicted upside of 13.87% based on their 12-month price targets.

What analysts cover IDEXX Laboratories?

IDEXX Laboratories has been rated by Atlantic Securities, Barclays, JPMorgan Chase & Co., and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:IDXX) was last updated on 3/22/2023 by MarketBeat.com Staff